Menu

Javascript is not activated in your browser. This website needs javascript activated to work properly.
You are here

Detecting EGFR alterations in clinical specimens-pitfalls and necessities.

Author:
  • Sofi Isaksson
  • Pär-Ola Bendahl
  • Annette Salomonsson
  • Mats Jönsson
  • Monica Haglund
  • Alexander Gaber
  • Karin Jirström
  • Per Jönsson
  • Åke Borg
  • Leif Johansson
  • Johan Staaf
  • Maria Planck
Publishing year: 2013
Language: English
Pages: 755-764
Publication/Series: Virchows Archiv: an international journal of pathology
Volume: 463
Issue: 6
Document type: Journal article
Publisher: Springer

Abstract english

We investigated the epidermal growth factor receptor (EGFR) status in early stage lung cancer in Southern Sweden, a population for which there are no previous reports on the EGFR mutation frequency. Three hundred fifty small cell lung cancers, adenocarcinomas (AC), squamous cell carcinomas (SqCC), and large cell carcinomas were analyzed using a combination of techniques for the analysis of protein expression, gene copy numbers, and mutations. Immunohistochemical (IHC) staining with antibodies for the EGFR mutations L858R and del E746-A750 revealed intratumoral heterogeneity and several discrepant cases when compared to mutation-specific polymerase chain reaction (PCR)-based analysis. The frequencies of these two mutations, when considering IHC staining with mutation-specific antibodies in a cohort of 298 cases and subsequent confirmation by PCR, were 10 % in AC and <2 % in SqCC. Furthermore, screening by sequencing of EGFR in a cohort of 52 lung AC and squamous carcinomas demonstrated a more diverse mutation spectrum, not covered by the mutation-specific antibodies. High expression of total EGFR protein was correlated to high gene copy numbers but did not reflect the mutational status of the tumors. We believe that the mutation spectra in a Southern Swedish population is too diverse to be covered by the mutation-specific antibodies, and we also raise some other issues regarding the use of the mutation-specific antibodies, for example concerning heterogeneous expression of the mutated protein, optimal antibody dilution, and discrepancies between staining results and PCR.

Keywords

  • Cancer and Oncology

Other

Published
  • Research Group Lung Cancer
  • ISSN: 1432-2307
Åke Borg
Åke Borg
E-mail: ake.borg [at] med.lu.se

Principal investigator

Oncology and Pathology, MV

+46 46 275 25 52

MV 404 C21B2

90

Project manager

Familial Breast Cancer

90

Professor

Oncology and Pathology, MV

MV 404 C21C2

90